S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
66,000% upside on tiny biotech? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
66,000% upside on tiny biotech? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
66,000% upside on tiny biotech? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
66,000% upside on tiny biotech? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:VERA

Vera Therapeutics (VERA) Stock Forecast, Price & News

$9.31
+0.36 (+4.02%)
(As of 06/2/2023 ET)
Compare
Today's Range
$8.96
▼
$9.48
50-Day Range
$6.11
▼
$9.31
52-Week Range
$5.20
▼
$23.39
Volume
193,736 shs
Average Volume
662,059 shs
Market Capitalization
$412.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Vera Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
26.2% Upside
$11.75 Price Target
Short Interest
Healthy
11.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.26 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.88) to ($2.68) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

373rd out of 983 stocks

Pharmaceutical Preparations Industry

177th out of 486 stocks

See Top Rated MarketRank™ Stocks Here

VERA stock logo

About Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERA Stock News Headlines

May 24, 2023 | msn.com
Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023
May 24, 2023 | proactiveinvestors.com
Marker Therapeutics' adds cell and gene therapy manufacturing to immunotherapy platform
June 3, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 16, 2023 | americanbankingnews.com
Brokers Set Expectations for Vera Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:VERA)
May 15, 2023 | americanbankingnews.com
Vera Therapeutics (NASDAQ:VERA) PT Raised to $9.00 at Wedbush
May 13, 2023 | uk.finance.yahoo.com
Vera Therapeutics, Inc. (VERA)
May 13, 2023 | americanbankingnews.com
Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $10.00 by Analysts at HC Wainwright
May 12, 2023 | msn.com
Wedbush Maintains Vera Therapeutics Inc - (VERA) Neutral Recommendation
June 3, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
May 12, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Finch Therapeutics Group (FNCH), Kezar Life Sciences (KZR)
May 12, 2023 | msn.com
Recap: Vera Therapeutics Q1 Earnings
May 11, 2023 | finance.yahoo.com
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
May 11, 2023 | finance.yahoo.com
Should You Buy Vera Therapeutics (VERA) Ahead of Earnings?
May 8, 2023 | benzinga.com
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
May 4, 2023 | finance.yahoo.com
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 2, 2023 | marketwatch.com
Polycythemia Vera Drug Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2031
May 1, 2023 | marketwatch.com
An In-Depth Analysis of the Global Polycythemia Vera Treatment Market Scope and its rapid growing 5.4% CAGR forcasted from 2023 - 2030
April 16, 2023 | marketwatch.com
Global Polycythemia Vera Drug Market 360-Degree Study with Current and Future Trends 2023 – 2030 By VMReports
April 16, 2023 | americanbankingnews.com
JPMorgan Chase & Co. Lowers Vera Therapeutics (NASDAQ:VERA) Price Target to $22.00
April 12, 2023 | msn.com
JP Morgan Maintains Vera Therapeutics, Inc. (VERA) Overweight Recommendation
April 5, 2023 | americanbankingnews.com
Beth C. Seidenberg Purchases 2,300 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock
April 4, 2023 | americanbankingnews.com
Jefferies Financial Group Comments on Vera Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:VERA)
April 1, 2023 | marketwatch.com
Friday 3/31 Insider Buying Report: PED, VERA
March 31, 2023 | americanbankingnews.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires $13,270.92 in Stock
March 31, 2023 | americanbankingnews.com
Insider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Buys 1,633 Shares of Stock
March 31, 2023 | americanbankingnews.com
Vera Therapeutics, Inc. to Post Q1 2023 Earnings of ($0.60) Per Share, Wedbush Forecasts (NASDAQ:VERA)
March 31, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for Vera Therapeutics, Inc. Raised by HC Wainwright (NASDAQ:VERA)
See More Headlines

VERA Price History

VERA Company Calendar

Last Earnings
3/28/2023
Today
6/02/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VERA
CUSIP
N/A
CIK
1831828
Web
veratx.com
Phone
650-770-0077
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.75
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+26.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,050,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-88.38%
Return on Assets
-65.71%

Debt

Debt-to-Equity Ratio
0.16
Current Ratio
8.69
Quick Ratio
8.69

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.56 per share
Price / Book
2.60

Miscellaneous

Outstanding Shares
44,260,000
Free Float
34,258,000
Market Cap
$409.85 million
Optionable
Not Optionable
Beta
-0.52

Key Executives

  • Dr. Marshall Fordyce M.D.Dr. Marshall Fordyce M.D. (Age 48)
    Founder, Pres, CEO & Director
    Comp: $715.36k
  • Mr. Sean P. Grant M.B.A. (Age 37)
    Chief Financial Officer
    Comp: $506.83k
  • Dr. Celia Lin M.D. (Age 47)
    Chief Medical Officer
    Comp: $645.82k
  • Mr. Joseph R. Young M.B.A. (Age 49)
    Sr. VP of Fin. & Chief Accounting Officer
  • Mr. Julien E. Capers J.D.
    VP & Head of Legal
  • Ms. Kelly Rauber
    VP & Head of HR
  • Mr. Tom Doan (Age 50)
    Sr. VP of Devel. Operations
  • Ms. Lauren Frenz (Age 37)
    Chief Bus. Officer
  • Dr. Joanne Curley Ph.D. (Age 53)
    Chief Devel. Officer
  • Dr. Neeraj Pakala M.B.A.
    Ph.D., Sr. VP of Product Devel. & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VERA Stock - Frequently Asked Questions

Should I buy or sell Vera Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VERA shares.
View VERA analyst ratings or view top-rated stocks.

What is Vera Therapeutics' stock price forecast for 2023?

4 brokers have issued 1 year price objectives for Vera Therapeutics' shares. Their VERA share price forecasts range from $6.00 to $22.00. On average, they predict the company's share price to reach $11.75 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price.
View analysts price targets for VERA or view top-rated stocks among Wall Street analysts.

How have VERA shares performed in 2023?

Vera Therapeutics' stock was trading at $19.35 at the beginning of the year. Since then, VERA shares have decreased by 52.1% and is now trading at $9.26.
View the best growth stocks for 2023 here.

When is Vera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our VERA earnings forecast.

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) released its quarterly earnings results on Tuesday, March, 28th. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.93) by $0.26.

What ETF holds Vera Therapeutics' stock ?

ALPS Medical Breakthroughs ETF holds 27,629 shares of VERA stock, representing 0.18% of its portfolio.

When did Vera Therapeutics IPO?

(VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Vera Therapeutics' stock symbol?

Vera Therapeutics trades on the NASDAQ under the ticker symbol "VERA."

Who are Vera Therapeutics' major shareholders?

Vera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (13.10%), Carlyle Group Inc. (6.69%), Commodore Capital LP (6.38%), BlackRock Inc. (3.19%), International Biotechnology Trust PLC (2.26%) and Sectoral Asset Management Inc. (1.36%). Insiders that own company stock include Beth C Seidenberg, Carlyle Group Inc, Joanne Curley, Llp Abingworth, Marshall Fordyce, Patrick G Enright, Sean Grant and Sofinnova Venture Partners X,.
View institutional ownership trends.

How do I buy shares of Vera Therapeutics?

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vera Therapeutics' stock price today?

One share of VERA stock can currently be purchased for approximately $9.26.

How much money does Vera Therapeutics make?

Vera Therapeutics (NASDAQ:VERA) has a market capitalization of $409.85 million. The company earns $-89,050,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis.

How can I contact Vera Therapeutics?

The official website for the company is veratx.com. The company can be reached via phone at 650-770-0077 or via email at ir@veratx.com.

This page (NASDAQ:VERA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -